625 related articles for article (PubMed ID: 9746960)
1. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R
Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E1 infusion compared with prostacyclin infusion in patients with refractory heart failure: effects on hemodynamics and neurohumoral variables.
Pacher R; Stanek B; Hülsmann M; Bojic A; Berger R; Frey B; Siegel A; Kos T; Ogris E; Grimm M; Laufer G
J Heart Lung Transplant; 1997 Aug; 16(8):878-81. PubMed ID: 9286780
[TBL] [Abstract][Full Text] [Related]
4. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
[TBL] [Abstract][Full Text] [Related]
5. Effect of prostaglandin E1 infusion on kidney function in patients with severe heart failure.
Wutte M; Hülsmann M; Berger R; Siegel A; Stanek B; Pacher R
J Heart Lung Transplant; 1996 Mar; 15(3):317-8. PubMed ID: 8777218
[No Abstract] [Full Text] [Related]
6. Acceptance of a pump-driven infusion therapy with prostaglandin E1 as a bridge to heart transplantation.
Daneschvar H; Pacher R; Rödler S; Stanek B; Hülsmann M; Grimm M; Laufer G; Wolner E; Bunzel B
Wien Klin Wochenschr; 1996; 108(16):510-4. PubMed ID: 8840497
[TBL] [Abstract][Full Text] [Related]
7. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E1--bridge to cardiac transplantation. Technique, dosage, results.
Pacher R; Stanek B; Hülsmann M; Berger R; Siegel A; Daneschvar H; Rödler S; Frey B; Grimm M; Laufer G
Eur Heart J; 1997 Feb; 18(2):318-29. PubMed ID: 9043849
[TBL] [Abstract][Full Text] [Related]
9. [Effect of prostaglandin E1 on extravascular lung water in patients with severe heart failure].
Lenz K; Kranz A; Kramer L; Buder R; Schollmayer E
Wien Klin Wochenschr; 1996; 108(16):505-9. PubMed ID: 8967094
[TBL] [Abstract][Full Text] [Related]
10. [Role of prostaglandins in regulation of kidney function in heart failure].
Riegger AJ
Herz; 1991 Apr; 16(2):116-23. PubMed ID: 2066053
[TBL] [Abstract][Full Text] [Related]
11. Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failure.
Stanek B; Pacher R
Jpn Heart J; 1997 Jan; 38(1):53-65. PubMed ID: 9186281
[TBL] [Abstract][Full Text] [Related]
12. Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure.
Kos T; Pacher R; Wimmer A; Bojic A; Hülsmann M; Frey B; Mayer G; Yilmaz N; Skvarilova L; Spinar J; Vitovec J; Toman J; Woloszcuk W; Stanek B
Wien Klin Wochenschr; 1998 Feb; 110(3):89-95. PubMed ID: 9553203
[TBL] [Abstract][Full Text] [Related]
13. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
Cotter G; Weissgarten J; Metzkor E; Moshkovitz Y; Litinski I; Tavori U; Perry C; Zaidenstein R; Golik A
Clin Pharmacol Ther; 1997 Aug; 62(2):187-93. PubMed ID: 9284855
[TBL] [Abstract][Full Text] [Related]
14. [Recombinant human brain natriuretic peptide on the cardiac hemodynamics and renal function in dogs with heart failure].
Xu XW; Zeng GY; Yang Y; Liu HX
Yao Xue Xue Bao; 2002 Oct; 37(10):758-62. PubMed ID: 12567856
[TBL] [Abstract][Full Text] [Related]
15. [Prostaglandin E1 for prevention of contrast medium-induced kidney dysfunction].
Koch JA; Sketch M; Brinker J; Bernink PJ
Rofo; 1999 Jun; 170(6):557-63. PubMed ID: 10420905
[TBL] [Abstract][Full Text] [Related]
16. Benefit of prostaglandin infusion in severe heart failure: preliminary clinical experience of repetitive administration.
Serra W; Musiari L; Ardissino D; Gherli T; Montanari A
Int J Cardiol; 2011 Jan; 146(1):e10-5. PubMed ID: 19176262
[TBL] [Abstract][Full Text] [Related]
17. The effects of prostaglandin E1 on non-pulmonary organ function during clinical acute respiratory failure. The Prostaglandin E1 Study Group.
Slotman GJ; Kerstein MD; Bone RC; Silverman H; Maunder R; Hyers TM; Ursprung JJ
J Trauma; 1992 Apr; 32(4):480-8; discussion 488-9. PubMed ID: 1569622
[TBL] [Abstract][Full Text] [Related]
18. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F
Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
[TBL] [Abstract][Full Text] [Related]
19. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.
Brienza N; Malcangi V; Dalfino L; Trerotoli P; Guagliardi C; Bortone D; Faconda G; Ribezzi M; Ancona G; Bruno F; Fiore T
Crit Care Med; 2006 Mar; 34(3):707-14. PubMed ID: 16505657
[TBL] [Abstract][Full Text] [Related]
20. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine].
Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M
Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
